Limits...
Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

Luvai A, Mbagaya W, Hall AS, Barth JH - Clin Med Insights Cardiol (2012)

Bottom Line: Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties.It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages.In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX.

ABSTRACT
Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.

No MeSH data available.


Related in: MedlinePlus

CHD event rate in primary prevention trials.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3303484&req=5

f1-cmc-6-2012-017: CHD event rate in primary prevention trials.

Mentions: These results compare favourably with other primary prevention trials using different statins. WOSCOPS (West of Scotland Coronary Prevention Study) showed that pravastatin 40 mg in men with moderate hypercholesterolaemia reduced incidence of myocardial infarction and cardiovascular death by 31%.41 Similarly, AFCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) demonstrated that lovastatin 20–40 mg daily reduced risk of first major coronary event by 37% in men and women with average LDL-C and below average HDL-C when compared with placebo.42 In the ASCOT lipid lowering arm, atorvastatin 10 mg reduced the incidence of myocardial infarction, stroke and cardiovascular death by 36% compared to placebo.9Figure 1 shows the CHD event reduction in primary prevention trials.


Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

Luvai A, Mbagaya W, Hall AS, Barth JH - Clin Med Insights Cardiol (2012)

CHD event rate in primary prevention trials.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3303484&req=5

f1-cmc-6-2012-017: CHD event rate in primary prevention trials.
Mentions: These results compare favourably with other primary prevention trials using different statins. WOSCOPS (West of Scotland Coronary Prevention Study) showed that pravastatin 40 mg in men with moderate hypercholesterolaemia reduced incidence of myocardial infarction and cardiovascular death by 31%.41 Similarly, AFCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) demonstrated that lovastatin 20–40 mg daily reduced risk of first major coronary event by 37% in men and women with average LDL-C and below average HDL-C when compared with placebo.42 In the ASCOT lipid lowering arm, atorvastatin 10 mg reduced the incidence of myocardial infarction, stroke and cardiovascular death by 36% compared to placebo.9Figure 1 shows the CHD event reduction in primary prevention trials.

Bottom Line: Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties.It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages.In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX.

ABSTRACT
Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.

No MeSH data available.


Related in: MedlinePlus